An overview on therapeutic efficacy and challenges of nanoparticles in blood cancer therapy

Cancer is a disease with limited therapeutic options, despite tremendous improvements in medical research and technology. Cancer metastasis and recurrence are major causes of disability and death. Traditional cancer treatments have many limitations, prompting nanotechnology innovation for more precise and less harmful cancer treatment, also known as cancer nanomedicine. In recent years, novel biomolecule-stabilized nanomaterials have emerged as prominent next-generation materials. Nanoparticles, facilitated by advances in nanotechnology, provide possibilities for effective blood cancer therapy. Nanoparticles are amenable to modification. They can be designed to target and control the dose of drug that enter the target region. As a result, nanoparticles may enhance drug effectiveness while reducing negative effects. Several experimental difficulties must be overcome to get nanoparticle treatment to the bedside. Finally it is vital to develop effective formulations that can address the aforementioned concerns while also offering precision targeting of tumour areas without affecting healthy tissue survival. This review primarily focuses on the highlights of current research progress using nanoparticles to deliver various blood cancer therapeutic medicines to illustrate nanoparticles' promise in leukemia, myeloma, and lymphoma therapy. Finally, we explore prospects and possible initiatives for potential therapeutic nanomedicine research.(c) 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Automated summary

Cancer is a disease with limited therapeutic options, and traditional cancer treatments have many limitations. Nanotechnology innovation, known as cancer nanomedicine, offers more precise and less harmful cancer treatment. Nanoparticles, with their ability to be modified and targeted, have the potential for effective blood cancer therapy by enhancing drug effectiveness while reducing negative effects. However, there are experimental difficulties that need to be addressed, and effective formulations that can target tumor areas without affecting healthy tissue survival need to be developed.